The health company founded by Dr. Rath is unique in the world: all the profit it makes go to a non-profit foundation

Recognise the signs of the times!

Reputable cancer research journal invites Dr. Rath to be a reviewer – and then retracts…

We are at a turning point in the history of medicine, moving from a medicine that serves the interests of the pharmaceutical investment industry, to a medicine serving the people. This goal, based on Dr. Rath’s scientific discoveries, is the foundation and impetus for the work of our Health Alliance.

Developments in recent weeks have shown how close we have come to achieving this goal through the ongoing and increasing confirmation of the findings of Dr. Rath’s scientific research. It is as though the floodgates have opened and all of a sudden there is a surge in the number of new studies proving the effectiveness of vitamins and other micronutrients in combating cancer. The following events also show clearly how incisive this turning point is:

On 5 August 2008, Dr. Rath was officially invited by the editor-in-chief of the “International Journal of Cancer” (IJC) Professor Harald zur Hausen, to be a scientific consultant for this journal. Besides being editor-in-chief of the IJC, Professor zur Hausen was also Director of the German Cancer Research Centre (DKFZ) in Heidelberg for two decades.

For nearly half a century Professor zur Hausen has been an exponent of pharma-orientated cancer research. His invitation to Dr. Rath, at this point in time, is not mere chance. It highlights the fact that international cancer research is changing course and is finally starting to accept that vitamins and other micronutrients have a major part to play in the battle against the cancer epidemic.

There can be absolutely no doubt that this change is due to the important advances in micronutrient research made by Dr. Rath and his team in the field of cancer control.

Given the historic significance of this situation, and based on the scientific facts which are now clear for all to see, in his response Dr. Rath invited the International Journal of Cancer and the German Cancer Research Centre to join efforts to eradicate cancer, as a fatal disease, for all future generations.

Professor zur Hausen and other proponents of pharma-oriented cancer research in Germany, as well as the relevant government ministers and political decision-makers, must now realise that such collaboration in the search for a natural, scientifically-based means of combating cancer will serve the interests of millions of cancer patients and, indeed, of all humanity.

We, therefore, invite you, Professor zur Hausen and others in leading positions, to communicate your support for Dr. Rath’s proposal in an email or letter. We believe it is important that Professor zur Hausen, together with his colleagues at the DKFZ and the international research community, be encouraged to put aside all inconsequential considerations and accept Dr. Rath’s invitation to engage in constructive dialogue and productive collaboration – in the interests of people all over the world.

Indeed, it is clear that such encouragement is necessary, since resolve seems to be somewhat thin on the ground, as demonstrated by the fact that Professor zur Hausen evidently got cold feet and suddenly wished to hear nothing more about his own invitation – which he had followed up with a “reminder”. This sudden memory loss, easily remedied by the emails received and published here, does not in the least alter the fact that it is high time for a profound rethink of pharmaceutically oriented medicine and medical research.

Please, therefore, write to Professor zur Hausen and the other people listed below. Ask Professor zur Hausen why he suddenly changed his mind and about his sudden memory lapse. If you are one of the numerous cancer patients with positive personal experiences about micronutrients, you can also enclose your own story in order to stress your point.

Please remember to send us a copy for our own files.

Editor-in-Chief of the International Journal of Cancer

Prof. Dr. Harald zur Hausen
International Journal of Cancer
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuenheimer Feld 242
69120 Heidelberg
Tel: 06221-423850
Fax: 06221-423851

Directors of the German Cancer Research Institute

Prof. Dr. Otmar D. Wiestler
DKFZ scientific foundation directorate
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: 06221-42-2850/51
Fax: 06221- 42-2840

Dr. Jörg Hoheisel
Chairman of the DKFZ board of science
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: 06221-42-2868/4680
Fax: 06221-42-4682

Ministerialdirektor Dr. rer. nat. Peter Lange
Chairman of the Heidelberg DKFZ board of trustees
c/o Bundesministerium für Bildung und Forschung
[Federal department for education and research]
Friedrichstr.130 B
10117 Berlin
Tel: 030-18-57-5105/5102
Fax: 030-18-57-8-5507

Assistant secretary Dr. phil. Heribert Knorr
Deputy chairman of the Heidelberg DKFZ board of trustees
c/o Ministerium für Wissenschaft, Forschung und Kunst
[Department for science, research and art]
Königsstraße 46
70173 Stuttgart
Tel: 0711-279-3301
Fax: 0711-279-3080

Prof. Dr. Carl-Henrik Heldin
Chairman of the Heidelberg DKFZ scientific committee
c/o Ludwig Institute for Cancer Research
Box 595
751 24 Uppsala / Sweden
Tel: +46 18 160401


Professor Harald zur Hausen
Editor in Chief
International Journal of Cancer
Deutsches Krebsforschungs-Zentrum (DKFZ)

August 13, 2008

Dear Professor zur Hausen,

On August 5, 2008 I received a letter signed by you inviting me to become a reviewer for the International Journal of Cancer (IJC) one of the most influential journals in cancer research. Beside your position as the Editor in Chief of the IJC, you have been chairman of the board of the German Cancer Research Centre (DKFZ) in Heidelberg for two decades, one of the world’s leading cancer research institutions.

In your letter you invite me to review a paper submitted to your journal for publication, documenting the value of ascorbic acid (vitamin C) in the fight against cancer. As the primary reason for this invitation to become a reviewer for your journal you state: “Because of your expertise and experience” in the field of cancer research. I can only interpret this statement as the official recognition of the key role of micronutrients in the control of cancers for which my research team and I have been fighting for more than a decade.

For your entire life you have been a prominent representative of conventional cancer approaches including toxic chemotherapy, radiotherapy and other approaches that primarily served one goal: to use the cancer epidemic as a global market for the pharmaceutical investment business with patented drugs.

For you to contact me – an outspoken critic of these conventional approaches to cancer and a scientific pioneer for new and natural approaches to cancer – was no coincidence. Your decision recognizes two important facts: 1. The deadlocks of pharmaceutically driven approaches to cancer and 2. The compelling perspectives of micronutrients as powerful preventive and therapeutic agents in the control of, essentially, all forms of human cancer.

With your letter you recognize the urgent need for a reorientation of cancer research to specifically include micronutrients in the world-wide fight against cancer. For that decision you should be commended. At the same time, I am fully aware that this step was not voluntary but was compelled by the simple fact that the breathtaking perspective of the natural control of cancer can no longer be ignored. With the world’s media regularly reporting the potential of vitamins and other micronutrients in reversing cancer, the dam is broken.

Considering the magnitude of negligence and obstruction towards micronutrients from the side of pharmaceutical medicine and considering the deadly consequences of this opposition for millions of cancer patients, your letter marks a turning point. It is obvious, however, that such a turning point in history cannot be guided by those who share responsibility for – or have at least tolerated – one of the darkest chapters in the history of mankind: the medical genocide in cancer.

In this situation, I have decided to respond to your letter in the form of an Open Letter to be shared with those most concerned about the way forward: The millions of cancer patients around the world. I am addressing you:

Before outlining the way forward, I consider it my duty to raise some of the questions from a consternated and outraged public you and your colleagues will have to answer in the months to come:

While the truth about the life-saving role of micronutrients in the fight against cancer was obstructed over decades, more than six million cancer patients worldwide died each year. They paid the ultimate price for the obstruction of the truth in the interests of the pharmaceutical investment business with the cancer epidemic. In light of this historic failure it would be naïve to think that a solution can come from those researchers that were largely responsible for this tragedy – or at least tolerated it.


In the interest of millions of cancer patients I therefore consider it incumbent upon me to direct the way forward. Here is what needs to be done immediately:

In the interest of millions of people, these tasks need to be tackled immediately. Considering the immense task to redirect cancer research on a global level, your invitation for me to join your journal as a reviewer is a drop in the ocean.

I am inviting you and your research colleagues to join us in a vigorous international effort with the defined goal to end the cancer epidemic forever. The scientific rationale to reach this goal is available. What needs to be done now is to organize a global effort to end cancer, involving science, medicine, politics and all other sectors of society.

With millions of lives at stake, if you stay indifferent now, history will judge you. If you decide to act, we will join our forces towards this great goal all mankind has been waiting for. If this is the goal, my research team and I are ready to cooperate with your journal and your research colleagues at every level.

As a first step we propose to jointly organize a public symposium between your journal, the DKFZ and our research institute. At this symposium the best researchers from the DKFZ and from our research team would present their research to an audience of patients, doctors and the public at large. Such a symposium could serve as the beginning of an international campaign carried by our research institutes and others who will join us towards the eradication of cancer.

I am looking forward to your response.

Sincerely yours,

Matthias Rath, M.D.